Tags

Type your tag names separated by a space and hit enter

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
Vaccine. 2018 06 07; 36(24):3468-3476.V

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.

Authors+Show Affiliations

Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea.Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.Division of VAX R&D, Life Science Research Institute, SK Chemical, Seongnam 12771, Republic of Korea.Division of Biotechnology, Chonbuk National University, Iksan 570-752, Republic of Korea. Electronic address: leesangm@jbnu.ac.kr.Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29739720

Citation

Jung, Seo-Yeon, et al. "Heterologous Prime-boost Vaccination With Adenoviral Vector and Protein Nanoparticles Induces Both Th1 and Th2 Responses Against Middle East Respiratory Syndrome Coronavirus." Vaccine, vol. 36, no. 24, 2018, pp. 3468-3476.
Jung SY, Kang KW, Lee EY, et al. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018;36(24):3468-3476.
Jung, S. Y., Kang, K. W., Lee, E. Y., Seo, D. W., Kim, H. L., Kim, H., Kwon, T., Park, H. L., Kim, H., Lee, S. M., & Nam, J. H. (2018). Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine, 36(24), 3468-3476. https://doi.org/10.1016/j.vaccine.2018.04.082
Jung SY, et al. Heterologous Prime-boost Vaccination With Adenoviral Vector and Protein Nanoparticles Induces Both Th1 and Th2 Responses Against Middle East Respiratory Syndrome Coronavirus. Vaccine. 2018 06 7;36(24):3468-3476. PubMed PMID: 29739720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. AU - Jung,Seo-Yeon, AU - Kang,Kyung Won, AU - Lee,Eun-Young, AU - Seo,Dong-Won, AU - Kim,Hong-Lim, AU - Kim,Hak, AU - Kwon,TaeWoo, AU - Park,Hye-Lim, AU - Kim,Hun, AU - Lee,Sang-Myeong, AU - Nam,Jae-Hwan, Y1 - 2018/05/05/ PY - 2017/11/28/received PY - 2018/04/25/revised PY - 2018/04/27/accepted PY - 2018/5/10/pubmed PY - 2018/9/27/medline PY - 2018/5/10/entrez KW - Adenovirus 5 KW - Heterologous prime–boost KW - MERS-CoV KW - Th1 KW - Th2 KW - Vaccine SP - 3468 EP - 3476 JF - Vaccine JO - Vaccine VL - 36 IS - 24 N2 - The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/29739720/Heterologous_prime_boost_vaccination_with_adenoviral_vector_and_protein_nanoparticles_induces_both_Th1_and_Th2_responses_against_Middle_East_respiratory_syndrome_coronavirus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(18)30598-X DB - PRIME DP - Unbound Medicine ER -